HR Execs on the Move

KLOwen Braces

www.klowenbraces.com

 
The KLOwen Orthodontics System greatly increases orthodontists​ capacity & profitability without compromising quality.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Dan Lopez
Vice President of Sales Profile

Similar Companies

Zavante Therapeutics

Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Integrated Project Services

IPS-Integrated Project Services, LLC is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve operations.

USA Rapid Test

COVID Tests, Rapid Test, Protocols, Atmofizer, Air Purification, Antigen Test, Antibody Test, My Protect Kit, Coronavirus Detection, David Lee Jensen, Tampa FL

Long Term Care Pharmacy Alliance

Long Term Care Pharmacy Alliance is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.